147 related articles for article (PubMed ID: 30144454)
1. A new platinum-based prodrug candidate: Its anticancer effects in B50 neuroblastoma rat cells.
Rangone B; Ferrari B; Astesana V; Masiello I; Veneroni P; Zanellato I; Osella D; Bottone MG
Life Sci; 2018 Oct; 210():166-176. PubMed ID: 30144454
[TBL] [Abstract][Full Text] [Related]
2. New Platinum-Based Prodrug Pt(IV)Ac-POA: Antitumour Effects in Rat C6 Glioblastoma Cells.
Ferrari B; Urselli F; Gilodi M; Camuso S; Priori EC; Rangone B; Ravera M; Veneroni P; Zanellato I; Roda E; Osella D; Bottone MG
Neurotox Res; 2020 Jan; 37(1):183-197. PubMed ID: 31240667
[TBL] [Abstract][Full Text] [Related]
3. [Pt(O,O'-acac)(γ-acac)(DMS)] versus cisplatin: apoptotic effects in B50 neuroblastoma cells.
Grimaldi M; Santin G; Insolia V; Dal Bo V; Piccolini VM; Veneroni P; Barni S; Verri M; De Pascali SA; Fanizzi FP; Bernocchi G; Bottone MG
Histochem Cell Biol; 2016 May; 145(5):587-601. PubMed ID: 26748644
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects after treatment with platinum compounds, cisplatin and [Pt(O,O'-acac)(γ-acac)(DMS)]: Autophagy activation in rat B50 neuroblastoma cells.
Grimaldi M; Bo VD; Ferrari B; Roda E; De Luca F; Veneroni P; Barni S; Verri M; De Pascali SA; Fanizzi FP; Bernocchi G; Bottone MG
Toxicol Appl Pharmacol; 2019 Feb; 364():1-11. PubMed ID: 30529627
[TBL] [Abstract][Full Text] [Related]
5. An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.
Gabano E; Ravera M; Zanellato I; Tinello S; Gallina A; Rangone B; Gandin V; Marzano C; Bottone MG; Osella D
Dalton Trans; 2017 Oct; 46(41):14174-14185. PubMed ID: 28984330
[TBL] [Abstract][Full Text] [Related]
6. A New Platinum-Based Prodrug Candidate for Chemotherapy and Its Synergistic Effect With Hadrontherapy: Novel Strategy to Treat Glioblastoma.
Ferrari B; Roda E; Priori EC; De Luca F; Facoetti A; Ravera M; Brandalise F; Locatelli CA; Rossi P; Bottone MG
Front Neurosci; 2021; 15():589906. PubMed ID: 33828444
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo antitumor activity of the novel trinuclear platinum complex BBR 3464 in neuroblastoma.
Riccardi A; Meco D; Ferlini C; Servidei T; Carelli G; Segni G; Manzotti C; Riccardi R
Cancer Chemother Pharmacol; 2001 Jun; 47(6):498-504. PubMed ID: 11459202
[TBL] [Abstract][Full Text] [Related]
8. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
[TBL] [Abstract][Full Text] [Related]
9. Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1.
Xu Z; Hu W; Wang Z; Gou S
Eur J Med Chem; 2017 Dec; 141():211-220. PubMed ID: 29031068
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial fusion: a mechanism of cisplatin-induced resistance in neuroblastoma cells?
Santin G; Piccolini VM; Barni S; Veneroni P; Giansanti V; Dal Bo V; Bernocchi G; Bottone MG
Neurotoxicology; 2013 Jan; 34():51-60. PubMed ID: 23103224
[TBL] [Abstract][Full Text] [Related]
11. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
Huang X; Wang M; Wang C; Hu W; You Q; Yang Y; Yu C; Liao Z; Gou S; Wang H
Bioorg Chem; 2019 Nov; 92():103236. PubMed ID: 31494328
[TBL] [Abstract][Full Text] [Related]
12. Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression.
Jin S; Guo Y; Song D; Zhu Z; Zhang Z; Sun Y; Yang T; Guo Z; Wang X
Inorg Chem; 2019 May; 58(9):6507-6516. PubMed ID: 31013065
[TBL] [Abstract][Full Text] [Related]
13. Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(IV) prodrug with unique mode of action.
Ma L; Ma R; Wang Y; Zhu X; Zhang J; Chan HC; Chen X; Zhang W; Chiu SK; Zhu G
Chem Commun (Camb); 2015 Apr; 51(29):6301-4. PubMed ID: 25644651
[TBL] [Abstract][Full Text] [Related]
14. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
Chen F; Qin X; Xu G; Gou S; Jin X
Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821
[TBL] [Abstract][Full Text] [Related]
15. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
Ma R; Wang Y; Yan L; Ma L; Wang Z; Chan HC; Chiu SK; Chen X; Zhu G
Chem Commun (Camb); 2015 May; 51(37):7859-62. PubMed ID: 25854514
[TBL] [Abstract][Full Text] [Related]
16. Different patterns of apoptosis in response to cisplatin in B50 neuroblastoma rat cells.
Santin G; Piccolini VM; Veneroni P; Barni S; Bernocchi G; Bottone MG
Histol Histopathol; 2011 Jul; 26(7):831-42. PubMed ID: 21630213
[TBL] [Abstract][Full Text] [Related]
17. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent Pt
Ma L; Wang N; Ma R; Li C; Xu Z; Tse MK; Zhu G
Angew Chem Int Ed Engl; 2018 Jul; 57(29):9098-9102. PubMed ID: 29806087
[TBL] [Abstract][Full Text] [Related]
18. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance.
Li L; Huang X; Huang R; Gou S; Wang Z; Wang H
Eur J Med Chem; 2018 Aug; 156():666-679. PubMed ID: 30031977
[TBL] [Abstract][Full Text] [Related]
19. Pt(IV) Bifunctional Prodrug Containing 2-(2-Propynyl)octanoato Axial Ligand: Induction of Immunogenic Cell Death on Colon Cancer.
Sabbatini M; Zanellato I; Ravera M; Gabano E; Perin E; Rangone B; Osella D
J Med Chem; 2019 Apr; 62(7):3395-3406. PubMed ID: 30879295
[TBL] [Abstract][Full Text] [Related]
20. Indirubin-3'-oxime induces mitochondrial dysfunction and triggers growth inhibition and cell cycle arrest in human neuroblastoma cells.
Liao XM; Leung KN
Oncol Rep; 2013 Jan; 29(1):371-9. PubMed ID: 23117445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
